Tofacitinib versus tocilizumab: comparison of CDAI-based improvements at 12 months in patients with RA after IPTW adjustment for time-varying confounders
| bDMARD-naïve patients with RA | Previous bDMARD-failure patients with RA | |||
| Adjusted OR* (95% CI) | P value | Adjusted OR* (95% CI) | P value | |
| Remission (CDAI ≤2.8) | 4.13 (2.18 to 7.82) | <0.001 | 1.12 (0.51 to 2.41) | 0.78 |
| Remission or low CDAI (≤10) | 2.57 (1.23 to 5.35) | 0.012 | 1.11 (0.63 to 1.94) | 0.73 |
| CDAI85† (major response) | 4.22 (2.26 to 7.88) | <0.001 | 0.85 (0.42 to 1.70) | 0.64 |
| CDAI70† (moderate response) | 3.27 (1.72 to 6.23) | <0.001 | 1.38 (0.76 to 2.50) | 0.29 |
| CDAI50† (minor response) | 1.77 (0.85 to 3.69) | 0.13 | 1.18 (0.67 to 2.08) | 0.56 |
| MCID-based improvement‡ | 2.99 (1.19 to 7.50) | 0.020 | 0.79 (0.43 to 1.45) | 0.45 |
*IPTW-adjusted ORs (95% CI) of tofacitinib versus tocilizumab were determined for each of the CDAI-based improvement measures according to univariable logistic regression analyses. A stabilised IPTW was created based on PS estimations at baseline, 3, 6, 9 and 11 months and used as the weight for outcome modelling at 12 months.
†Defined as achieving and maintaining ≥50% improvement of CDAI (CDAI50), ≥70% (CDAI70) and ≥85% (CDAI85) during the 12-month treatment.
‡Defined as CDAI reduction >12 for patients starting with a high CDAI and CDAI reduction >6 for those starting with a moderate CDAI at 12 months of treatment.
bDMARD, biological disease-modifying antirheumatic drug; CDAI, clinical disease activity index; IPTW, inverse probability of treatment weighting; MCID, minimal clinically important difference; RA, rheumatoid arthritis.